All the news Showing 9 of 9 articles from: EgyptGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Hepatocellular carcinoma (HCC) Models can help predict liver cancer in people cured of hepatitis C Liz Highleyman / 17 September 2020 Three new methods using readily available clinical parameters can help predict who will develop hepatocellular carcinoma (HCC) after achieving sustained virological response to hepatitis C treatment, according to studies presented at the recent 2020 Digital ... Screening policy 30 million screened for hepatitis C in four months in Egypt Keith Alcorn / 11 April 2019 Egypt screened almost 30 million people for hepatitis C in the first four months of a national screening programme that kicked off in October 2018, Egyptian researchers announced at The International Liver Congress ... Screening policy Same-day hepatitis C treatment initiation can be achieved at large scale, Egyptian pilot study shows Keith Alcorn / 11 April 2019 Screening for hepatitis C, confirmation of chronic infection by point-of-care viral load testing and treatment initiation can all be achieved on the same day in a community setting, Egyptian researchers reported at The ... Treatment outcomes Generic DAAs achieve excellent cure rates in Egypt matching those of branded drugs at a fraction of the cost Michael Carter / 01 February 2019 Generic direct-acting antivirals (DAAs) are just as effective and safe as their branded equivalents for the treatment of chronic hepatitis C virus (HCV) infection, according to Egyptian research published in Liver International. Generics achieved ... Genotype 4 Ravidasvir plus sofosbuvir demonstrates high cure rate for people with hepatitis C genotype 4 Liz Highleyman / 02 March 2016 Sofosbuvir plus the investigational HCV NS5A inhibitor ravidasvir, with or without ribavirin, cured 95 to 100% of people with hepatitis C virus (HCV) genotype 4, the most common type in Egypt, ... Genotype 4 Sofosbuvir & ravidasvir delivers high sustained response rates for genotype 4 hepatitis C patients Liz Highleyman / 17 November 2015 A regimen of sofosbuvir and the pan-genotypic HCV NS5A inhibitor ravidasvir, with or without ribavirin, demonstrated sustained response rates ranging from 86% to 100% in the largest phase 3 trial to ... International policy World Health Organization calls for ambitious global targets for viral hepatitis control Keith Alcorn / 03 September 2015 The World Health Organization (WHO) is calling for ambitious new global targets for diagnosis, treatment and cure of viral hepatitis, signalling a major increase in momentum towards elimination of viral hepatitis by 2030. Dr ... Genotype 4 AbbVie 2-drug combination + ribavirin achieves 100% cure in previously untreated genotype 4 hepatitis C Keith Alcorn / 22 April 2014 A combination of two direct-acting antivirals developed by AbbVie cured 100% of previously untreated patients with hepatitis C genotype 4 infection when used with ribavirin, Christophe Hézode reported on Friday at the ... Deciding when and how to treat HCV Model shows that HCV therapy for patients with more severe fibrosis cost-effective in Egypt Michael Carter / 24 February 2014 Lack of resources means that Egypt should prioritise hepatitis C virus (HCV) treatment for patients with more advanced disease, according to a mathematical model published in the online edition of Clinical Infectious Diseases. Therapy ... ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive